About The Study: In an open-label trial in patients with heart failure with preserved ejection fraction with left ventricular ejection fraction of 60% or greater, mavacamten, a cardiac myosin inhibitor, was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in left ventricular ejection fraction observed.
Corresponding Authors: To contact the corresponding authors, email Sanjiv J. Shah, MD, ( sanjiv.shah@northwestern.edu ) and Scott D. Solomon, MD, ( ssolomon@bwh.harvard.edu ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.3810)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the Heart Failure Society of America Annual Scientific Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.3810?guestAccessKey=90c1d87e-0a72-447a-b6a6-e9cdb9d39cbb&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=093024
JAMA Cardiology